Search Within

Martin Henner Voss

  1. "Genitourinary Oncology Service"
Formats
  1. Meeting Abstract (150)
  2. Journal Article (122)
  3. Review (6)
  4. Editorial (5)
  5. Guidelines (2)
  6. Research Letter (2)
  7. Correspondence (1)
Groups
  1. Department of Medicine (288)
  2. Genitourinary Oncology Service (288)
  3. Solid Tumor Oncology Division (288)
  4. Human Oncology and Pathogenesis Program (104)
  5. Weinberg Fellows (104)
  6. Surgery (103)

More Groups

People
  1. Robert Motzer (176)
  2. Abraham Hakimi (95)
  3. Darren Feldman (80)
  4. Chung-Han Lee (75)
  5. Maria Carlo (65)
  6. Ritesh Kotecha (63)

More People

Years
  1. 2025 (6)
  2. 2024 (15)
  3. 2023 (21)
  4. 2022 (24)
  5. 2021 (30)
  6. 2020 (23)

More Years

Publications
  1. Journal of Clinical Oncology (116)
  2. Clinical Cancer Research (18)
  3. BJU International (15)
  4. Annals of Oncology (13)
  5. Journal for ImmunoTherapy of Cancer (12)
  6. Clinical Genitourinary Cancer (8)

More Publications

Publishers
  1. American Society of Clinical Oncology (120)
  2. American Association for Cancer Research (26)
  3. Wiley Blackwell (22)
  4. Elsevier Inc. (21)
  5. Oxford University Press (18)
  6. Biomed Central Ltd (15)

More Publishers

Results (288)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Nivolumab plus cabozantinib in patients with non-clear cell renal cell carcinoma: Updated results from a phase 2 trial
    Meeting Abstract

    Lee, C. H.; Fitzgerald, K. N.; Voss, M. H.; Carlo, M. I.; Knezevic, A.; Peralta, L.; Chen, Y. B.; Zucker, M.; Lefkowitz, R. A.; Reznik, E.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Efficacy and safety of atezolizumab plus cabozantinib vs cabozantinib alone after progression with prior immune checkpoint inhibitor (ICI) treatment in metastatic renal cell carcinoma (RCC): Primary PFS analysis from the phase 3, randomized, open-label CONTACT-03 study
    Meeting Abstract

    Choueiri, T. K.; Albiges, L.; Tomczak, P.; Suáez, C.; Voss, M. H.; de Velasco, G.; Chahoud, J.; Procopio, G.; Mahammedi, H.; Zengerling, F.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Immunometabolic coevolution defines unique microenvironmental niches in ccRCC
    Journal Article

    Tang, C.; Xie, A. X.; Liu, E. M.; Kuo, F.; Kim, M.; DiNatale, R. G.; Golkaram, M.; Chen, Y. B.; Gupta, S.; Motzer, R. J.; more...
    Cell Metabolism (2023)

    Fulltext@MSK | Save
  • Atezolizumab plus cabozantinib versus cabozantinib monotherapy for patients with renal cell carcinoma after progression with previous immune checkpoint inhibitor treatment (CONTACT-03): A multicentre, randomised, open-label, phase 3 trial
    Journal Article

    Pal, S. K.; Albiges, L.; Tomczak, P.; Suárez, C.; Voss, M. H.; de Velasco, G.; Chahoud, J.; Mochalova, A.; Procopio, G.; Mahammedi, H.; more...
    Lancet (2023)

    Fulltext@MSK | Save
  • Prognostic factors for survival in patients undergoing surveillance after cytoreductive nephrectomy
    Journal Article

    Reese, S. W.; Khaleel, S.; Silagy, A.; Xie, A.; Eismann, L.; Vazquez-Rivera, K.; Oparanozie, A.; Patil, S.; Coleman, J.; Motzer, R.; more...
    Journal of Urology (2023)

    Fulltext@MSK | Save
  • Reply by authors
    Correspondence

    Reese, S. W.; Khaleel, S.; Silagy, A.; Xie, A.; Eismann, L.; Vazquez-Rivera, K.; Oparanozie, A.; Patil, S.; Coleman, J.; Motzer, R.; more...
    Journal of Urology (2023)

    Fulltext@MSK | Save
  • Pathologic response and histologic features of cytoreductive nephrectomy (CN) following immunotherapy (IO) for patients with metastatic renal cell carcinoma (RCC)
    Meeting Abstract

    Wu, C. Y.; Reese, S.; Al-Ahmadie, H.; Fine, S.; Gopalan, A.; Sarungbam, J.; Sirintrapun, S. J.; Kotecha, R.; Voss, M.; Coleman, J.; more...
    Laboratory Investigation (2023)

    Fulltext@MSK | Save
  • Progression-free survival after second line of therapy for metastatic clear cell renal cell carcinoma in patients treated with first-line immunotherapy combinations
    Research Letter

    Fitzgerald, K. N.; Duzgol, C.; Knezevic, A.; Shapnik, N.; Kotecha, R.; Aggen, D. H.; Carlo, M. I.; Shah, N. J.; Voss, M. H.; Feldman, D. R.; more...
    European Urology (2023)

    Fulltext@MSK | Save
  • STARLITE 2: Phase 2 study of nivolumab plus (177)lutetium-labeled anti–carbonic anhydrase IX (CAIX) monoclonal antibody girentuximab ((177)Lu-girentuximab) in patients (pts) with advanced clear cell renal cell carcinoma (ccRCC)
    Meeting Abstract

    Feldman, D. R.; Motzer, R. J.; Knezevic, A.; Lee, C. H.; Voss, M. H.; Lyashchenko, S. K.; Park, H.; Larson, S. M.; Pandit-Taskar, N.
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Impact of sarcomatoid features on treatment outcomes in metastatic clear cell renal cell carcinoma treated with first-line immunotherapy combinations
    Meeting Abstract

    Fitzgerald, K. N.; Duzgol, C.; Knezevic, A.; Shapnik, N.; Kotecha, R. R.; Aggen, D. H.; Carlo, M. I.; Shah, N. J.; Voss, M. H.; Feldman, D. R.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save